When XDx yesterday filed to raise up to $86.3 million in an IPO, the Brisbane, Calif., company joined just a handful of similar molecular-diagnostic companies to test the public markets. XDx ...

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company that discovers, develops and commercializes high value, non-invasive tests to monitor immune status in transplant ...

PARIS & BRISBANE, Calif.--(BUSINESS WIRE)--Regulatory News: Diaxonhit (Paris:ALEHT), the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company ...

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced the ...

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire/ -- XDx, Inc., a molecular diagnostics company, announced today that it has completed a $20 million Series D private equity financing. Sprout Group led ...

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc. has received market clearance from the U.S. Food and Drug Administration (FDA) for AlloMap® Molecular Expression Testing. The AlloMap Test is a noninvasive ...

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, announced today that it has ...